Literature DB >> 26253305

A combination of molecular markers and clinical features improve the classification of pancreatic cysts.

Simeon Springer1, Yuxuan Wang1, Marco Dal Molin2, David L Masica3, Yuchen Jiao1, Isaac Kinde1, Amanda Blackford4, Siva P Raman5, Christopher L Wolfgang6, Tyler Tomita7, Noushin Niknafs7, Christopher Douville7, Janine Ptak1, Lisa Dobbyn1, Peter J Allen8, David S Klimstra9, Mark A Schattner10, C Max Schmidt11, Michele Yip-Schneider12, Oscar W Cummings12, Randall E Brand13, Herbert J Zeh14, Aatur D Singhi15, Aldo Scarpa16, Roberto Salvia17, Giuseppe Malleo17, Giuseppe Zamboni18, Massimo Falconi19, Jin-Young Jang20, Sun-Whe Kim20, Wooil Kwon20, Seung-Mo Hong21, Ki-Byung Song22, Song Cheol Kim22, Niall Swan23, Jean Murphy23, Justin Geoghegan24, William Brugge25, Carlos Fernandez-Del Castillo26, Mari Mino-Kenudson27, Richard Schulick28, Barish H Edil28, Volkan Adsay29, Jorge Paulino30, Jeanin van Hooft31, Shinichi Yachida32, Satoshi Nara32, Nobuyoshi Hiraoka32, Kenji Yamao33, Susuma Hijioka33, Schalk van der Merwe34, Michael Goggins35, Marcia Irene Canto36, Nita Ahuja37, Kenzo Hirose37, Martin Makary37, Matthew J Weiss37, John Cameron37, Meredith Pittman2, James R Eshleman1, Luis A Diaz38, Nickolas Papadopoulos1, Kenneth W Kinzler1, Rachel Karchin39, Ralph H Hruban40, Bert Vogelstein1, Anne Marie Lennon41.   

Abstract

BACKGROUND & AIMS: The management of pancreatic cysts poses challenges to both patients and their physicians. We investigated whether a combination of molecular markers and clinical information could improve the classification of pancreatic cysts and management of patients.
METHODS: We performed a multi-center, retrospective study of 130 patients with resected pancreatic cystic neoplasms (12 serous cystadenomas, 10 solid pseudopapillary neoplasms, 12 mucinous cystic neoplasms, and 96 intraductal papillary mucinous neoplasms). Cyst fluid was analyzed to identify subtle mutations in genes known to be mutated in pancreatic cysts (BRAF, CDKN2A, CTNNB1, GNAS, KRAS, NRAS, PIK3CA, RNF43, SMAD4, TP53, and VHL); to identify loss of heterozygozity at CDKN2A, RNF43, SMAD4, TP53, and VHL tumor suppressor loci; and to identify aneuploidy. The analyses were performed using specialized technologies for implementing and interpreting massively parallel sequencing data acquisition. An algorithm was used to select markers that could classify cyst type and grade. The accuracy of the molecular markers was compared with that of clinical markers and a combination of molecular and clinical markers.
RESULTS: We identified molecular markers and clinical features that classified cyst type with 90%-100% sensitivity and 92%-98% specificity. The molecular marker panel correctly identified 67 of the 74 patients who did not require surgery and could, therefore, reduce the number of unnecessary operations by 91%.
CONCLUSIONS: We identified a panel of molecular markers and clinical features that show promise for the accurate classification of cystic neoplasms of the pancreas and identification of cysts that require surgery.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; IPMN; Molecular; Pancreatic Cyst

Mesh:

Substances:

Year:  2015        PMID: 26253305      PMCID: PMC4782782          DOI: 10.1053/j.gastro.2015.07.041

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

1.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-del Castillo; Volkan Adsay; Suresh Chari; Massimo Falconi; Jin-Young Jang; Wataru Kimura; Philippe Levy; Martha Bishop Pitman; C Max Schmidt; Michio Shimizu; Christopher L Wolfgang; Koji Yamaguchi; Kenji Yamao
Journal:  Pancreatology       Date:  2012-04-16       Impact factor: 3.996

2.  851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital.

Authors:  Nakul P Valsangkar; Vicente Morales-Oyarvide; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

3.  Base-calling of automated sequencer traces using phred. II. Error probabilities.

Authors:  B Ewing; P Green
Journal:  Genome Res       Date:  1998-03       Impact factor: 9.043

4.  Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.

Authors:  Jian Wu; Yuchen Jiao; Marco Dal Molin; Anirban Maitra; Roeland F de Wilde; Laura D Wood; James R Eshleman; Michael G Goggins; Christopher L Wolfgang; Marcia I Canto; Richard D Schulick; Barish H Edil; Michael A Choti; Volkan Adsay; David S Klimstra; G Johan A Offerhaus; Alison P Klein; Levy Kopelovich; Hannah Carter; Rachel Karchin; Peter J Allen; C Max Schmidt; Yoshiki Naito; Luis A Diaz; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-08       Impact factor: 11.205

5.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

6.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

Authors:  David L Masica; Rachel Karchin
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

7.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

8.  Flow cytometric studies on the relationship between DNA content and clinicopathologic features of pancreatic cancers.

Authors:  J Bocsi; C Berczi; G Balázs; K Lapis
Journal:  Anticancer Res       Date:  1998 May-Jun       Impact factor: 2.480

9.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

10.  FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing.

Authors:  Isaac Kinde; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more
  136 in total

1.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Clinical approach to incidental pancreatic cysts.

Authors:  Austin L Chiang; Linda S Lee
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers.

Authors:  Tatsuo Hata; Marco Dal Molin; Seung-Mo Hong; Koji Tamura; Masaya Suenaga; Jun Yu; Hiraku Sedogawa; Matthew J Weiss; Christopher L Wolfgang; Anne Marie Lennon; Ralph H Hruban; Michael G Goggins
Journal:  Clin Cancer Res       Date:  2017-02-01       Impact factor: 12.531

Review 4.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

Review 5.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

Review 6.  Molecular Diagnostics and Testing for Pancreatic Cysts.

Authors:  Jaime de la Fuente; Shounak Majumder
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-27

7.  Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.

Authors:  Sandra Faias; Marlene Duarte; Cristina Albuquerque; João Pereira da Silva; Ricardo Fonseca; Ruben Roque; Antonio Dias Pereira; Paula Chaves; Marília Cravo
Journal:  Dig Dis Sci       Date:  2018-05-24       Impact factor: 3.199

8.  Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance.

Authors:  Masaya Suenaga; Jun Yu; Koji Shindo; Koji Tamura; Jose Alejandro Almario; Christopher Zaykoski; P Dane Witmer; Shahriar Fesharakizadeh; Michael Borges; Anne-Marie Lennon; Eun-Ji Shin; Marcia Irene Canto; Michael Goggins
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

Review 9.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 10.  Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas.

Authors:  Aadhithya Raman; Anne Marie Lennon
Journal:  Visc Med       Date:  2018-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.